Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicentre, Open Label, Non-controlled, Observational, 26-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus in Macedonia

NCT00842894 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00842894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00842894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicentre, Open Label, Non-controlled, Observational, 26-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus in Macedonia
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
May 31, 2009
Completion date
October 31, 2010
Enrollment
3,421 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2